Return on capital (ROC) is after tax rate of return on net business assets. ROIC is unaffected by changes in interest rates or company debt and equity structure. It measures business productivity performance.
Paying user area
Try for free
DexCom Inc. pages available for free this week:
- Income Statement
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Dividend Discount Model (DDM)
- Debt to Equity since 2005
- Price to Book Value (P/BV) since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to DexCom Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Return on Invested Capital (ROIC)
Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Net operating profit after taxes (NOPAT)1 | ||||||
Invested capital2 | ||||||
Performance Ratio | ||||||
ROIC3 | ||||||
Benchmarks | ||||||
ROIC, Competitors4 | ||||||
Abbott Laboratories | ||||||
Elevance Health Inc. | ||||||
Intuitive Surgical Inc. | ||||||
Medtronic PLC | ||||||
UnitedHealth Group Inc. |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 NOPAT. See details »
2 Invested capital. See details »
3 2022 Calculation
ROIC = 100 × NOPAT ÷ Invested capital
= 100 × ÷ =
4 Click competitor name to see calculations.
- Net Operating Profit After Taxes (NOPAT)
- The net operating profit after taxes demonstrated a significant improvement over the period analyzed. Initially, there was a negative value in 2018, indicating an operating loss after taxes. From 2019 onwards, NOPAT turned positive and increased substantially, reaching its peak in 2022. This pattern suggests enhanced operational efficiency and profitability over time, despite a decline in 2021 compared to 2020.
- Invested Capital
- The invested capital fluctuated during the period with a marked decrease in 2019 after 2018, followed by a substantial increase through 2021. In 2022, the invested capital decreased again but remained higher than the initial levels of 2018 and 2019. This variability may reflect strategic capital allocation adjustments or shifts in asset base and investment levels.
- Return on Invested Capital (ROIC)
- The return on invested capital exhibited strong volatility. It started with a negative return in 2018, turning positive and peaking in 2020. A significant reduction was observed in 2021, although the ROIC remained positive, highlighting reduced efficiency in capital utilization that year. The ROIC rebounded sharply in 2022 to levels close to the 2020 peak, indicating restored or improved profitability relative to invested capital.
- Overall Insights
- Collectively, the data indicate an initial period of operational and financial challenges in 2018, followed by consecutive improvements in profitability and return metrics from 2019 through 2020. The dip in 2021 may suggest operational difficulties or changes in capital management. The resurgence in both NOPAT and ROIC in 2022 suggests effective management actions or favorable market conditions leading to enhanced financial performance. The fluctuations in invested capital correspond with these profitability trends, reflecting dynamic capital allocation strategies over the five-year period.
Decomposition of ROIC
ROIC | = | OPM1 | × | TO2 | × | 1 – CTR3 | |
---|---|---|---|---|---|---|---|
Dec 31, 2022 | = | × | × | ||||
Dec 31, 2021 | = | × | × | ||||
Dec 31, 2020 | = | × | × | ||||
Dec 31, 2019 | = | × | × | ||||
Dec 31, 2018 | = | × | × |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 Operating profit margin (OPM). See calculations »
2 Turnover of capital (TO). See calculations »
3 Effective cash tax rate (CTR). See calculations »
The analysis of the financial ratios over the five-year period reveals significant variations in profitability, capital efficiency, tax management, and overall return on invested capital.
- Operating Profit Margin (OPM)
- The operating profit margin experienced a notable transformation from a negative margin of -10.39% in 2018 to positive territory in 2019 at 11.31%. It further increased to 16.7% in 2020 before declining to 11.41% in 2021. In 2022, it recovered to 14.69%. This indicates an overall improvement in operational profitability, albeit with some volatility, particularly a dip in 2021.
- Turnover of Capital (TO)
- Capital turnover showed significant fluctuation across the period. Starting at a low ratio of 0.71 in 2018, it sharply increased to 1.76 in 2019. The ratio then declined to 1.41 in 2020 and further to 1.29 in 2021, before rising again to 1.77 in 2022. This pattern suggests variable efficiency in using capital to generate revenues, with peaks in 2019 and 2022.
- 1 – Effective Cash Tax Rate (CTR)
- The metric measuring the proportion of earnings retained after cash taxes (1 – CTR) started at a full 100% in 2018, indicating no cash taxes paid or full retention of earnings. It decreased progressively each year to 90.13% in 2019, 91.38% in 2020, followed by further declines to 83.39% in 2021 and 82.15% in 2022. This trend implies an increasing cash tax burden over the years.
- Return on Invested Capital (ROIC)
- ROIC showed marked improvement from a negative -7.97% in 2018 to a high of 21.51% in 2020. After a dip to 12.27% in 2021, it rebounded to 21.37% in 2022. The overall pattern indicates enhanced effectiveness in generating returns from invested capital, notwithstanding the temporary decline in 2021.
Overall, the financial ratios reflect an underlying progression towards improved profitability and capital utilization, tempered by some fluctuations in both operational margin and capital turnover. Simultaneously, the rising cash tax impact may suggest increased tax liabilities or changes in tax strategy. The elevated ROIC in later years affirms an efficient allocation and utilization of invested capital despite interim variability.
Operating Profit Margin (OPM)
Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Net operating profit after taxes (NOPAT)1 | ||||||
Add: Cash operating taxes2 | ||||||
Net operating profit before taxes (NOPBT) | ||||||
Revenue | ||||||
Add: Increase (decrease) in deferred revenue | ||||||
Adjusted revenue | ||||||
Profitability Ratio | ||||||
OPM3 | ||||||
Benchmarks | ||||||
OPM, Competitors4 | ||||||
Abbott Laboratories | ||||||
Elevance Health Inc. | ||||||
Intuitive Surgical Inc. | ||||||
Medtronic PLC | ||||||
UnitedHealth Group Inc. |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2022 Calculation
OPM = 100 × NOPBT ÷ Adjusted revenue
= 100 × ÷ =
4 Click competitor name to see calculations.
The financial data exhibits several notable trends over the five-year period examined.
- Net Operating Profit Before Taxes (NOPBT)
- The net operating profit before taxes showed a significant turnaround from a negative position in 2018 to positive values in subsequent years. Starting at -107,202 thousand US dollars in 2018, it increased markedly to 166,800 thousand in 2019 and continued to grow, reaching 429,006 thousand in 2022. This progression reflects an overall improvement in operational profitability prior to tax expenses, with some fluctuations observed, particularly a decline in 2021 compared to 2020, but a strong recovery in 2022.
- Adjusted Revenue
- Revenue data reveals continuous growth across the timeframe. Beginning at 1,031,300 thousand US dollars in 2018, adjusted revenue expanded steadily each year, culminating at 2,920,700 thousand US dollars in 2022. This trend indicates consistent top-line expansion, suggesting successful market penetration or expansion strategies as well as possible pricing power or increased sales volume.
- Operating Profit Margin (OPM)
- The operating profit margin reflected meaningful improvement from a negative margin of -10.39% in 2018 to positive margins in all following years. The margin peaked at 16.7% in 2020 but experienced a decline to 11.41% in 2021 before slightly recovering to 14.69% in 2022. This pattern indicates increased operational efficiency and profitability but also suggests some volatility in cost management or revenue quality during the latter period.
In summary, the data demonstrates a company that has substantially increased both its revenue and profitability over the period, overcoming an initial loss to achieve solid operational success. The positive revenue trend alongside improvements in operating profit margin highlights effective scaling of operations, though some fluctuations in profitability margins warrant attention to cost control or revenue mix changes in recent years.
Turnover of Capital (TO)
Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Revenue | ||||||
Add: Increase (decrease) in deferred revenue | ||||||
Adjusted revenue | ||||||
Invested capital1 | ||||||
Efficiency Ratio | ||||||
TO2 | ||||||
Benchmarks | ||||||
TO, Competitors3 | ||||||
Abbott Laboratories | ||||||
Elevance Health Inc. | ||||||
Intuitive Surgical Inc. | ||||||
Medtronic PLC | ||||||
UnitedHealth Group Inc. |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 Invested capital. See details »
2 2022 Calculation
TO = Adjusted revenue ÷ Invested capital
= ÷ =
3 Click competitor name to see calculations.
The annual financial data reveals several key trends in the company's performance over the five-year period.
- Adjusted Revenue
- Adjusted revenue shows a consistent upward trend from 2018 through 2022. Starting at approximately $1.03 billion in 2018, revenue increased steadily each year, reaching nearly $2.92 billion by 2022. This represents almost a threefold increase over the five-year span, indicating substantial growth in the company's top-line performance.
- Invested Capital
- The invested capital figures display more variability. In 2018, invested capital was about $1.45 billion, which then significantly decreased to $836 million in 2019. Following this decline, invested capital rose again to $1.37 billion in 2020 and continued to grow to approximately $1.90 billion in 2021, before slightly declining to $1.65 billion in 2022. This pattern suggests fluctuations in investment strategies or asset base adjustments during the period.
- Turnover of Capital (TO)
- The turnover ratio, reflecting the efficiency of capital usage, also shows notable shifts. Starting at 0.71 in 2018, it increased sharply to 1.76 in 2019, indicating improved capital efficiency. However, it then declined to 1.41 in 2020 and further to 1.29 in 2021, suggesting a temporary reduction in efficiency. By 2022, the turnover ratio rebounded to 1.77, the highest level in the observed period, which may imply enhanced utilization of capital invested in the most recent year.
Overall, the data indicates strong revenue growth alongside fluctuations in invested capital and capital turnover. The rebound in turnover ratio in 2022 coupled with the highest revenue level suggests a positive alignment of capital investment and revenue generation efficiency toward the end of the period.
Effective Cash Tax Rate (CTR)
Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Net operating profit after taxes (NOPAT)1 | ||||||
Add: Cash operating taxes2 | ||||||
Net operating profit before taxes (NOPBT) | ||||||
Tax Rate | ||||||
CTR3 | ||||||
Benchmarks | ||||||
CTR, Competitors4 | ||||||
Abbott Laboratories | ||||||
Elevance Health Inc. | ||||||
Intuitive Surgical Inc. | ||||||
Medtronic PLC | ||||||
UnitedHealth Group Inc. |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2022 Calculation
CTR = 100 × Cash operating taxes ÷ NOPBT
= 100 × ÷ =
4 Click competitor name to see calculations.
- Cash Operating Taxes
- The cash operating taxes demonstrate a consistent and substantial increase over the five-year period, rising from $8,239 thousand in 2018 to $76,556 thousand in 2022. This represents a nearly tenfold growth, indicating a significant rise in tax payments in absolute terms.
- Net Operating Profit Before Taxes (NOPBT)
- NOPBT shows a notable improvement from a negative figure of -$107,202 thousand in 2018 to a positive and increasing trend reaching $429,006 thousand in 2022. After turning positive in 2019, the profit before taxes more than doubled in 2020, experienced a slight decline in 2021, and then increased significantly again in 2022, reflecting overall strong operational profitability growth.
- Effective Cash Tax Rate (CTR)
- The effective cash tax rate was not reported in 2018; starting from 2019, it initially decreased from 9.87% to 8.62% in 2020, followed by a marked increase to 16.61% in 2021 and further to 17.85% in 2022. This rising tax rate trend from 2020 onwards indicates an escalating tax burden relative to the net operating profit before taxes.
- Overall Analysis
- The data reveals a robust improvement in operating profit before taxes alongside a steady growth in cash operating taxes. Despite a dip in the effective cash tax rate in 2020, the subsequent upward trend suggests increasing tax obligations as profits grow. The interplay of rising profitability and increasing tax rates has led to a substantial rise in actual cash tax payments, which reflects the company's expanding tax liabilities in line with enhanced earning performance.